文献速递生殖医学

胚胎游离DNA与滋养外胚层活检一致性多中心前瞻研究

Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts.
PubMed 文献 · Am J Obstet Gynecol · 2020-05-26

该多中心前瞻性观察研究纳入371名20-44岁患者的1301枚第6/7天囊胚,比较胚胎游离DNA无创检测与滋养外胚层活检的一致性。胚胎游离DNA与滋养外胚层活检总体一致率为78.2%(866/1108),各中心间无显著差异;当培养实验室步骤严格控制时一致率超过86%。

要点

  • 胚胎游离DNA与滋养外胚层活检一致率为78.2%,各中心间无显著差异。
  • 假阴性率8.3%,假阳性率12.4%,各中心灵敏度76.5%-91.3%、特异度64.7%-93.3%。
  • 胚胎游离DNA可能同时来源于内细胞团和滋养外胚层。

核心结论

  • 胚胎游离DNA无创检测与滋养外胚层活检在此大型多中心系列中显示高一致性。

研究设计与样本

  • 前瞻性观察性研究的中期分析,覆盖4大洲8家IVF中心。
  • 纳入371名20-44岁患者的406个IVF周期,共1301枚第6/7天囊胚。
  • 新鲜卵母细胞经ICSI或IVF受精,媒体收集前不允许辅助孵化或玻璃化。
  • 第4天起培养至少40小时后收集单个囊胚培养液,随后行滋养外胚层活检和囊胚玻璃化。
  • 对81枚捐赠用于研究的非整倍体囊胚另行内细胞团和滋养外胚层活检。

主要发现

  • 胚胎游离DNA分析与滋养外胚层活检一致率为78.2%(866/1108)。
  • 各中心一致率范围72.5%-86.3%,无显著差异。
  • 当培养实验室所有既定步骤受控以最小化母源和操作者污染时,一致率超过86%。
  • 各中心灵敏度范围76.5%-91.3%,特异度范围64.7%-93.3%。
  • 假阴性率8.3%(92/1108),假阳性率12.4%(137/1108)。

临床怎么用

  • 无创胚胎游离DNA检测可用于优先筛选整倍体胚胎,避免有创活检并降低成本。
  • 有望扩大辅助生殖技术中胚胎非整倍体检测的可及人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The recent identification of embryonic cell-free DNA in spent blastocyst media has opened a new era of possibilities for noninvasive embryo aneuploidy testing in assisted reproductive technologies. Yet, previous studies assessing a limited number of embryos reported variable concordance between embryonic cell-free DNA and trophectoderm biopsies, thus questioning the validity of this approach. OBJECTIVE: This study aimed to evaluate the concordance and reproducibility of testing embryonic cell-free DNA vs trophectoderm DNA obtained from the same embryo in a large sample of human blastocysts and to assess the contribution of the inner cell mass and trophectoderm to embryonic cell-free DNA released to the culture media. STUDY DESIGN: This is an interim analysis of a prospective, observational study among 8 in vitro fertilization centers in 4 continents to assess consistency between noninvasive embryo aneuploidy testing of embryonic cell-free DNA and conventional trophectoderm biopsy. The analysis included 1301 day-6/7 blastocysts obtained in 406 in vitro fertilization cycles from 371 patients aged 20-44 years undergoing preimplantation genetic testing for aneuploidy. Fresh oocytes underwent intracytoplasmic sperm injection or in vitro fertilization. No previous assisted hatching or vitrification was allowed before media collection. Individual spent blastocyst medium was collected from embryos cultured at least 40 hours from day 4. After media collection, conventional preimplantation genetic testing for aneuploidy, comprising trophectoderm biopsy and blastocyst vitrification, was performed. Embryonic cell-free DNA was analyzed blindly after embryo transfer. Inner cell mass and trophectoderm biopsies were also performed in a subset of 81 aneuploid blastocysts donated for research. RESULTS: Embryonic cell-free DNA analyses were 78.2% (866/1108) concordant with the corresponding trophectoderm biopsies. No significant differences were detected among centers ranging from 72.5% to 86.3%. Concordance rates exceeded 86% when all defined steps in the culture laboratory were controlled to minimize the impact of maternal and operator contamination. Sensitivity per center ranged from 76.5% to 91.3% and specificity from 64.7% to 93.3%. The false-negative rate was 8.3% (92/1108), and false-positive rate was 12.4% (137/1108). The 2 fertilization techniques provided similar sensitivity (80.9% vs 87.9%) and specificity (78.6% vs 69.9%). Multivariate analysis did not reveal any bias from patient clinical background, ovarian stimulation protocols, culture conditions, or embryo quality on testing accuracy of concordance. Moreover, concordances of embryonic cell-free DNA with trophectoderm and inner cell mass suggest that the embryonic cell-free DNA originates from both compartments of the human embryo. CONCLUSION: Noninvasive analysis of embryonic cell-free DNA in spent blastocyst culture media demonstrates high concordance with trophectoderm biopsy results in this large multicenter series. A noninvasive approach for prioritizing embryo euploidy offers important advantages such as avoiding invasive embryo biopsy and decreased cost, potentially increasing accessibility for a wider patient population.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rubio C, Navarro-Sánchez L, García-Pascual CM, et al. Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts. Am J Obstet Gynecol. 2020. PMID: 32470458. doi:10.1016/j.ajog.2020.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。